{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:22:06Z","timestamp":1779358926909,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.cgh.2016.12.040","type":"journal-article","created":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T12:17:42Z","timestamp":1485173862000},"page":"260-267.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis"],"prefix":"10.1016","volume":"16","author":[{"given":"Moritz","family":"Peiseler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Liebscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcial","family":"Sebode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Zenouzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Hartl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanno","family":"Ehlken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Pannicke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Weiler-Normann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ansgar W.","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2016.12.040_bib1","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.12.040_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practise guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2016.12.040_bib3","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/hep.23924","article-title":"Application of the 2010 American Association for the Study of Liver Diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis","volume":"52","author":"Muratori","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.12.040_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/imj.1968.17.3.214","article-title":"Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality and survival","volume":"17","author":"Mistilis","year":"1968","journal-title":"Australas Ann Med"},{"key":"10.1016\/j.cgh.2016.12.040_bib5","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/gut.16.11.876","article-title":"Prednisone for chronic active liver disease: dose titration, standard dose and combination with azathioprine compound","volume":"16","author":"Summerskill","year":"1975","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2016.12.040_bib6","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1089-3261(02)00028-4","article-title":"Treatment strategies in autoimmune hepatitis","volume":"6","author":"Czaja","year":"2002","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2016.12.040_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/s-2002-35706","article-title":"Treatment of autoimmune hepatitis","volume":"22","author":"Czaja","year":"2002","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cgh.2016.12.040_bib8","first-page":"57","article-title":"Treatment of patients with severe autoimmune hepatitis","volume":"54","author":"Larsen","year":"2008","journal-title":"Minerva Gastroenterol Dietol"},{"key":"10.1016\/j.cgh.2016.12.040_bib9","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.12.040_bib10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"1","author":"Murray-Lyon","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2016.12.040_bib11","first-page":"1687","article-title":"Synthesis and anti-inflammatory properties of budesonide, a new non-halogenated glucocorticoid with high local activity","volume":"29","author":"Thal\u00e9n","year":"1979","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.cgh.2016.12.040_bib12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2036.1994.tb00334.x","article-title":"Oral budesonide for treatment of autoimmune chronic active hepatitis","volume":"8","author":"Danielsson","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2016.12.040_bib13","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.12.040_bib14","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1478-3231.2005.01122.x","article-title":"Budesonide in previously untreated autoimmune hepatitis","volume":"25","author":"Wiegand","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2016.12.040_bib15","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1053\/gast.2000.0010000001","article-title":"Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis","volume":"119","author":"Czaja","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.12.040_bib16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.12.040_bib17","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1155\/2008\/509459","article-title":"The use of budesonide in the treatment of autoimmune hepatitis in Canada","volume":"22","author":"Zandieh","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.12.040_bib18","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3748\/wjg.v12.i9.1362","article-title":"Budesonide induces complete remission in autoimmune hepatitis","volume":"12","author":"Csepregi","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.12.040_bib19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.autrev.2011.09.006","article-title":"Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome","volume":"11","author":"Efe","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cgh.2016.12.040_bib20","first-page":"611","article-title":"Autoimmune hepatitis in southern Israel: a 15-year multicenter study","volume":"14","author":"Delgado","year":"2013","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.cgh.2016.12.040_bib21","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/gut.2010.235259","article-title":"British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis","volume":"60","author":"Gleeson","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2016.12.040_bib22","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jpeds.2013.05.042","article-title":"Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents","volume":"163","author":"Woynarowski","year":"2013","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cgh.2016.12.040_bib23","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2010.09.017","article-title":"Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment","volume":"54","author":"Lohse","year":"2011","journal-title":"J\u00a0Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517300605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517300605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:24:18Z","timestamp":1761542658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356517300605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1542356517300605"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2016.12.040","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2016.12.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the AGA Institute","name":"copyright","label":"Copyright"}]}}